|
1
|
Wong MC, Jiang JY, Goggins WB, Liang M,
Fang Y, Fung FD, Leung C, Wang HH, Wong GL, Wong VW, et al:
International incidence and mortality trends of liver cancer: A
global profile. Sci Rep. 7:458462017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hadzic N and Finegold MJ: Liver neoplasia
in children. Clin Liver Dis. 15(443–462): vii–x. 2011.
|
|
4
|
Horton JD, Lee S, Brown SR, Bader J and
Meier DE: Survival trends in children with hepatoblastoma. Pediatr
Surg Int. 25:407–412. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Otte JB: Progress in the surgical
treatment of malignant liver tumors in children. Cancer Treat Rev.
36:360–371. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Davis GL, Dempster J, Meler JD, Orr DW,
Walberg MW, Brown B, Berger BD, O'Connor JK and Goldstein RM:
Hepatocellular carcinoma: Management of an increasingly common
problem. Proc. 21:266–280. 2008.
|
|
7
|
Dhanasekaran R, Limaye A and Cabrera R:
Hepatocellular carcinoma: Current trends in worldwide epidemiology,
risk factors, diagnosis, and therapeutics. Hepat Med. 4:19–37.
2012.PubMed/NCBI
|
|
8
|
Cox J and Weinman S: Mechanisms of
doxorubicin resistance in hepatocellular carcinoma. Hepat Oncol.
3:57–59. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
North BJ and Verdin E: Sirtuins:
Sir2-related NAD-dependent protein deacetylases. Genome Biol.
5:2242004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Canto C, Gerhart-Hines Z, Feige JN,
Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P and Auwerx
J: AMPK regulates energy expenditure by modulating NAD+
metabolism and SIRT1 activity. Nature. 458:1056–1060. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Satoh A, Brace CS, Rensing N, Cliften P,
Wozniak DF, Herzog ED, Yamada KA and Imai S: Sirt1 extends life
span and delays aging in mice through the regulation of Nk2
homeobox 1 in the DMH and LH. Cell Metab. 18:416–430. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Zhu Y, Xing S, Ma P and Lin D:
SIRT5 prevents cigarette smoke extract-induced apoptosis in lung
epithelial cells via deacetylation of FOXO3. Cell Stress
Chaperones. 20:805–810. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tseng AH, Shieh SS and Wang DL: SIRT3
deacetylates FOXO3 to protect mitochondria against oxidative
damage. Free Radic Biol Med. 63:222–234. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brunet A, Sweeney LB, Sturgill JF, Chua
KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, et
al: Stress-dependent regulation of FOXO transcription factors by
the SIRT1 deacetylase. Science. 303:2011–2015. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Simic P, Zainabadi K, Bell E, Sykes DB,
Saez B, Lotinun S, Baron R, Scadden D, Schipani E and Guarente L:
SIRT1 regulates differentiation of mesenchymal stem cells by
deacetylating β-catenin. EMBO Mol Med. 5:430–440. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jeong J, Juhn K, Lee H, Kim SH, Min BH,
Lee KM, Cho MH, Park GH and Lee KH: SIRT1 promotes DNA repair
activity and deacetylation of Ku70. Exp Mol Med. 39:8–13. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marquardt JU, Fischer K, Baus K, Kashyap
A, Ma S, Krupp M, Linke M, Teufel A, Zechner U, Strand D, et al:
Sirtuin-6-dependent genetic and epigenetic alterations are
associated with poor clinical outcome in hepatocellular carcinoma
patients. Hepatology. 58:1054–1064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ponugoti B, Kim DH, Xiao Z, Smith Z, Miao
J, Zang M, Wu SY, Chiang CM, Veenstra TD and Kemper JK: SIRT1
deacetylates and inhibits SREBP-1C activity in regulation of
hepatic lipid metabolism. J Biol Chem. 285:33959–33970. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang F, Nguyen M, Qin FX and Tong Q: SIRT2
deacetylates FOXO3a in response to oxidative stress and caloric
restriction. Aging Cell. 6:505–514. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin YH, Kim YJ, Kim DW, Baek KH, Kang BY,
Yeo CY and Lee KY: Sirt2 interacts with 14-3-3 beta/gamma and
down-regulates the activity of p53. Biochem Biophys Res Commun.
368:690–695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rothgiesser KM, Erener S, Waibel S,
Luscher B and Hottiger MO: SIRT2 regulates NF-κB dependent gene
expression through deacetylation of p65 Lys310. J Cell Sci.
123:4251–4258. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vaziri H, Dessain SK, Eaton Ng E, Imai SI,
Frye RA, Pandita TK, Guarente L and Weinberg RA: hSIR2SIRT1
functions as an NAD-dependent p53 deacetylase. Cell. 107:149–159.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Z, Bridges B, Olson J and Weinman SA:
The interaction between acetylation and serine-574 phosphorylation
regulates the apoptotic function of FOXO3. Oncogene. 36:1887–1898.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Paredes S, Villanova L and Chua KF:
Molecular pathways: Emerging roles of mammalian sirtuin SIRT7 in
cancer. Clin Cancer Res. 20:1741–1746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kaidi A, Weinert BT, Choudhary C and
Jackson SP: Human SIRT6 promotes DNA end resection through CtIP
deacetylation. Science. 329:1348–1353. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim HS, Xiao C, Wang RH, Lahusen T, Xu X,
Vassilopoulos A, Vazquez-Ortiz G, Jeong WI, Park O, Ki SH, et al:
Hepatic-specific disruption of SIRT6 in mice results in fatty liver
formation due to enhanced glycolysis and triglyceride synthesis.
Cell Metab. 12:224–236. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiao C, Kim HS, Lahusen T, Wang RH, Xu X,
Gavrilova O, Jou W, Gius D and Deng CX: SIRT6 deficiency results in
severe hypoglycemia by enhancing both basal and insulin-stimulated
glucose uptake in mice. J Biol Chem. 285:36776–36784. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhong L, D'Urso A, Toiber D, Sebastian C,
Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD,
Nir T, et al: The histone deacetylase Sirt6 regulates glucose
homeostasis via Hif1alpha. Cell. 140:280–293. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kugel S, Sebastian C, Fitamant J, Ross KN,
Saha SK, Jain E, Gladden A, Arora KS, Kato Y, Rivera MN, et al:
SIRT6 suppresses pancreatic cancer through control of Lin28b. Cell.
165:1401–1415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ioris RM, Galie M, Ramadori G, Anderson
JG, Charollais A, Konstantinidou G, Brenachot X, Aras E, Goga A,
Ceglia N, et al: SIRT6 suppresses cancer stem-like capacity in
tumors with PI3K activation independently of its deacetylase
activity. Cell Rep. 18:1858–1868. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sebastian C, Zwaans BM, Silberman DM,
Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber
D, et al: The histone deacetylase SIRT6 is a tumor suppressor that
controls cancer metabolism. Cell. 151:1185–1199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee N, Ryu HG, Kwon JH, Kim DK, Kim SR,
Wang HJ, Kim KT and Choi KY: SIRT6 depletion suppresses tumor
growth by promoting cellular senescence induced by DNA damage in
HCC. PLoS One. 11:e01658352016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ran LK, Chen Y, Zhang ZZ, Tao NN, Ren JH,
Zhou L, Tang H, Chen X, Chen K, Li WY, et al: SIRT6 overexpression
potentiates apoptosis evasion in hepatocellular carcinoma via
BCL2-associated X protein-dependent apoptotic pathway. Clin Cancer
Res. 22:3372–3382. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Z, Zhao J, Tikkhanovich I, Kuravi S,
Helzberd J, Dorko K, Roberts B, Kumer S and Weinman SA: Serine 574
phosphorylation alters transcriptional programming of FOXO3 by
selectively enhancing apoptotic gene expression. Cell Death Differ.
23:583–595. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang P, Tu B, Wang H, Cao Z, Tang M,
Zhang C, Gu B, Li Z, Wang L, Yang Y, et al: Tumor suppressor p53
cooperates with SIRT6 to regulate gluconeogenesis by promoting
foxO1 nuclear exclusion. Proc Natl Acad Sci U S A. 111:10684–10689.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tao R, Xiong X, DePinho RA, Deng CX and
Dong XC: FoxO3 transcription factor and Sirt6 deacetylase regulate
low density lipoprotein (LDL)-cholesterol homeostasis via control
of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene
expression. J Biol Chem. 288:29252–29259. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song MY, Wang J, Ka SO, Bae EJ and Park
BH: Insulin secretion impairment in Sirt6 knockout pancreatic beta
cells is mediated by suppression of the FoxO1-Pdx1-Glut2 pathway.
Sci Rep. 6:303212016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang F, Chan CH, Chen K, Guan X, Lin HK
and Tong Q: Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to
Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene.
31:1546–1557. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dobson M, Ramakrishnan G, Ma S, Kaplun L,
Balan V, Fridman R and Tzivion G: Bimodal regulation of FoxO3 by
AKT and 14-3-3. Biochim Biophys Acta. 1813:1453–1464. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kanfi Y, Shalman R, Peshti V, Pilosof SN,
Gozlan YM, Pearson KJ, Lerrer B, Moazed D, Marine JC, de Cabo R, et
al: Regulation of SIRT6 protein levels by nutrient availability.
FEBS Lett. 582:543–548. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Flick F and Luscher B: Regulation of
sirtuin function by posttranslational modifications. Front
Pharmacol. 3:292012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Caito S, Rajendrasozhan S, Cook S, Chung
S, Yao H, Friedman AE, Brookes PS and Rahman I: SIRT1 is a
redox-sensitive deacetylase that is post-translationally modified
by oxidants and carbonyl stress. FASEB J. 24:3145–3159. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sasaki T, Maier B, Koclega KD, Chruszcz M,
Gluba W, Stukenberg PT, Minor W and Scrable H: Phosphorylation
regulates SIRT1 function. PLoS One. 3:e40202008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zschoernig B and Mahlknecht U:
Carboxy-terminal phosphorylation of SIRT1 by protein kinase CK2.
Biochem Biophys Res Commun. 381:372–377. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Olsen JV, Blagoev B, Gnad F, Macek B,
Kumar C, Mortensen P and Mann M: Global, in vivo, and site-specific
phosphorylation dynamics in signaling networks. Cell. 127:635–648.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nasrin N, Kaushik VK, Fortier E, Wall D,
Pearson KJ, de Cabo R and Bordone L: JNK1 phosphorylates SIRT1 and
promotes its enzymatic activity. PLoS One. 4:e84142009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gao Z, Zhang J, Kheterpal I, Kennedy N,
Davis RJ and Ye J: Sirtuin 1 (SIRT1) protein degradation in
response to persistent c-Jun N-terminal kinase 1 (JNK1) activation
contributes to hepatic steatosis in obesity. J Biol Chem.
286:22227–22234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Van Meter M, Simon M, Tombline G, May A,
Morello TD, Hubbard BP, Bredbenner K, Park R, Sinclair DA, Bohr VA,
et al: JNK phosphorylates SIRT6 to stimulate DNA double-strand
break repair in response to oxidative stress by recruiting PARP1 to
DNA breaks. Cell Rep. 16:2641–2650. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kim J and Freeman MR: JNK/SAPK mediates
doxorubicin-induced differentiation and apoptosis in MCF-7 breast
cancer cells. Breast Cancer Res Treat. 79:321–328. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Calnan DR and Brunet A: The foxo code.
Oncogene. 27:2276–2288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Khongkow M, Olmos Y, Gong C, Gomes AR,
Monteiro LJ, Yagüe E, Cavaco TB, Khongkow P, Man EP, Laohasinnarong
S, et al: SIRT6 modulates paclitaxel and epirubicin resistance and
survival in breast cancer. Carcinogenesis. 34:1476–1486. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Elmali N, Baysal O, Harma A, Esenkaya I
and Mizrak B: Effects of resveratrol in inflammatory arthritis.
Inflammation. 30:1–6. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lee SM, Yang H, Tartar DM, Gao B, Luo X,
Ye SQ, Zaghouani H and Fang D: Prevention and treatment of diabetes
with resveratrol in a non-obese mouse model of type 1 diabetes.
Diabetologia. 54:1136–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Peck B, Chen CY, Ho KK, Di Fruscia P,
Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD and Lam EW: SIRT
inhibitors induce cell death and p53 acetylation through targeting
both SIRT1 and SIRT2. Mol Cancer Ther. 9:844–855. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jing H, Hu J, He B, Negrón Abril YL,
Stupinski J, Weiser K, Carbonaro M, Chiang YL, Southard T,
Giannakakou P, et al: A SIRT2-selective inhibitor promotes c-Myc
oncoprotein degradation and exhibits broad anticancer activity.
Cancer Cell. 29:297–310. 2016. View Article : Google Scholar : PubMed/NCBI
|
